Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

BACKGROUND: Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects are reported, with the major two being bleeding and ibrutinib-related atrial f...

Descripción completa

Detalles Bibliográficos
Autores principales: Reda, Gianluigi, Fattizzo, Bruno, Cassin, Ramona, Mattiello, Veronica, Tonella, Tatiana, Giannarelli, Diana, Massari, Ferdinando, Cortelezzi, Agostino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996546/
https://www.ncbi.nlm.nih.gov/pubmed/29891001
http://dx.doi.org/10.1186/s13045-018-0626-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996546/
https://www.ncbi.nlm.nih.gov/pubmed/29891001
http://dx.doi.org/10.1186/s13045-018-0626-0

Ejemplares similares